Martin Fitchet is CEO of Medicines for Malaria Venture, a Swiss foundation accelerating access to innovative antimalarial medicines. A U.K.-trained physician with more than 25 years in global health and research and development, he previously led Johnson & Johnson’s Global Public Health team, advancing treatments for diseases including TB, HIV, Ebola, and COVID-19.
Opinion: Drug resistance in malaria already led to a spike in deaths in the early 2000s. Now history may repeat itself — but we have the experience to avert this crisis.
